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Editorial T he Food and Drug Administration (FDA) has announced, in the Federal Register, a public hearing regarding the use of color in pharmaceutical product labels, labeling, and packaging. 1 It is their belief that there is little scientific evidence that applying color is effective in reducing medication errors, and I agree with this assessment. Searches of PubMed, Web of Science, the International Pharmaceutical Abstracts, and the Internet produce limited information on this subject. Nor is there much information on the problems presented with color coding or the use of color on medications or labeling regarding people with color-blindness.
Some of the concepts that will be considered are color coding, color differentiation, color branding, and color matching. Color coding is the use of color to aid in the classification and identification of a product. Color differentiation is the use of color to emphasize package information or distinguish one package from another. Color branding is used by a single manufacturer to differentiate one drug product from another (eg, insulin products). Color matching is the use of color to help with the assembling of a medical device (ie, yellow plug attaches to a yellow receptacle). A number of the manufacturers of drugs and medical devices are using at least one of these color schemes on some of their existing products, but there are no industry or regulatory standards.
The Institute for Safe Medication Practices has several reports on their Web site (www.ismp.org) regarding the impact of the application of color coding and the risk of medication errors. Not all of these reports are favorable. Some of the information indicates that the use of color coding could contribute to further medication errors instead of preventing one. 2, 3 In addition, the ability of the practitioner to correctly see the intended color needs to be considered. Not all humans see colors the same way, some of us are color blind, have a disease, or take medication that alters our visual perception or ability to differentiate between colors. 4,5,6,7,8 A person that is color blind (also referred to as color vision confusion) does not have a total loss of color vision, but does have problems distinguishing certain colors (ie, red and green). It is estimated that the 'red-green' color blindness occurs in one in 12 Caucasian, one in 20 Asian, and one in 25 African males; yet our traffic signals use red and green. 8 Color blindness occurs in females less often (0.4% to 2%). 9 These issues will also need to be considered prior to implementing any color-related guidelines.
The intent of this meeting is to obtain input regarding the benefits and potential drawbacks of applying color to drug packaging and labeling in order to help identify, classify, and differentiate those products. The FDA is looking for help in determining if the use of one or all of these schemes will be able to improve patient care and safety.
This meeting is scheduled for March 7, 2005 and will have occurred by the time most practitioners read this editorial. However, it is not too late to express your opinion. The deadline for written and electronic comments is April 7, 2005. Information on how to provide your written or electronic comments can be found at: http:// www.fda.gov/OHRMS/DOCKETS/ 98fr/05n-0036-nm00001.pdf.
It will be interesting to see the results from this meeting. Regardless of the outcome, this type of inquiry should be encouraged and funding for the necessary research should be made available. We can only hope that one or several of these methods can help to decrease the risk of a medication error in the future, but we can not rely on it to work 100% of the time. Any standard or regulation that is created from this process should be considered a method to help decrease the risk of errors and not a means to eliminate the risk. 
Medication Error Column Celebrates 30th Anniversary
Thirty years ago, Hospital Pharmacy began publication of a monthly medication error prevention column written by Michael R. Cohen, RPh, MS, ScD, FASHP which provides practitioners a chance to report, in confidence, errors and near misses that they experience as well as concerns they have about medication safety. In celebration, please review the first four errors reported in March 1975 that are still applicable today. 1 Error 1: An order was written, "4 U Lente Insulin."Because of poor handwriting, the U was mistaken for an O. The patient received 40 units of Lente insulin.
The Abbreviation "U" should not be used; the word "units" should be spelled out Error 2: An outpatient prescription was written Florinef #25 Sig: As Directed. The pharmacist mistook it for Fiorinal. If the handwriting has been studied carefully, the prescription would have been obvious. However, two out of five other pharmacists when asked hurriedly to read the prescription made the same mistake.
Pharmacists must take care in reading prescriptions. The prescribing physician was asked to indicate the desired strength and specific directions in the future. If he has done so originally, the pharmacist would not have made the error. Patient instructions are also necessary for proper compliance.
Error 3: An order was received in the pharmacy for "1 mg Synthroid." When the pharmacist checked the original order in the chart, he found that the physician had ordered .1 mg Synthroid. The decimal point was placed directly on a line on the order sheet and was not obvious.
The error was prevented. The confusion should have been avoided if the physician had written 0.1 mg. All labeling, formularies, and newsletters should also carry out this format. A long-range solution to this recurring problem is the use of the microgram designation for amounts less than 1 mg.
Error 4:
A physician gave a verbal order for 16 units of regular insulin. The individual taking the order thought the physician said 60. Sixty units were administered.
This type of error could be eliminated if no verbal orders were accepted for insulin. If verbal orders were required, the individual taking the order should read back carefully to the prescriber, "16, that is one-six units of regular insulin." Besides hearing the order correctly, the person involved must transcribe it onto the chart of the right patient.
